RGS' chart and momentum is looking strong. Looks like it is poised for a re-rate on the back of a good clinical agreement coming out of Japan, which as we have been advised can happen in the near term.
RGS Price at posting:
16.0¢ Sentiment: Buy Disclosure: Held